Net Income Common - Ryvu Therapeutics SA (WSE:RVU) - Alpha Spread
R

Ryvu Therapeutics SA
WSE:RVU

Watchlist Manager
Ryvu Therapeutics SA
WSE:RVU
Watchlist
Price: 54.2 PLN -0.18% Market Closed
Market Cap: 1.3B PLN
Have any thoughts about
Ryvu Therapeutics SA?
Write Note

Ryvu Therapeutics SA
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Ryvu Therapeutics SA
Net Income (Common) Peer Comparison

Comparables:
I
IGN
M
MDB
S
SLV

Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
R
Ryvu Therapeutics SA
WSE:RVU
Net Income (Common)
-zł93.9m
CAGR 3-Years
-32%
CAGR 5-Years
-47%
CAGR 10-Years
N/A
I
Inno-Gene SA
WSE:IGN
Net Income (Common)
-zł6.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-24%
M
Medicofarma Biotech SA
WSE:MDB
Net Income (Common)
-zł2.7m
CAGR 3-Years
-43%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Selvita SA
WSE:SLV
Net Income (Common)
zł65.3m
CAGR 3-Years
45%
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is Ryvu Therapeutics SA's Net Income (Common)?
Net Income (Common)
-93.9m PLN

Based on the financial report for Mar 31, 2024, Ryvu Therapeutics SA's Net Income (Common) amounts to -93.9m PLN.

What is Ryvu Therapeutics SA's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-47%

Over the last year, the Net Income (Common) growth was 7%. The average annual Net Income (Common) growth rates for Ryvu Therapeutics SA have been -32% over the past three years , -47% over the past five years .

Back to Top